Nephros Inc. (NASDAQ:NEPH) Short Interest Update

Nephros Inc. (NASDAQ:NEPH) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 3,625 shares, a decline of 49.9% from the November 30th total of 7,233 shares. Based on an average daily trading volume, of 67,084 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 67,084 shares, the short-interest ratio is presently 0.1 days.

Nephros Price Performance

NASDAQ NEPH traded down $0.30 on Friday, hitting $4.93. 20,894 shares of the company were exchanged, compared to its average volume of 57,515. Nephros has a twelve month low of $1.39 and a twelve month high of $6.42. The firm has a market capitalization of $52.39 million, a P/E ratio of 37.93 and a beta of 1.48. The company’s 50 day moving average price is $5.11 and its 200-day moving average price is $4.46.

Nephros (NASDAQ:NEPH) last released its earnings results on Thursday, November 6th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.05. Nephros had a net margin of 8.26% and a return on equity of 15.81%. The business had revenue of $4.76 million for the quarter, compared to the consensus estimate of $3.87 million.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NEPH. Wall Street Zen upgraded shares of Nephros to a “strong-buy” rating in a research report on Saturday, October 18th. Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Institutional Trading of Nephros

A number of hedge funds have recently modified their holdings of NEPH. Topline Capital Management LLC boosted its position in shares of Nephros by 24.9% in the third quarter. Topline Capital Management LLC now owns 596,300 shares of the company’s stock worth $2,820,000 after buying an additional 118,851 shares during the period. Geode Capital Management LLC lifted its stake in Nephros by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after acquiring an additional 2,898 shares in the last quarter. Citadel Advisors LLC boosted its position in Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after acquiring an additional 4,655 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in Nephros during the 3rd quarter worth about $64,000. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.